Lilly(Eli) & Co

+12.92 (+4.13%)
Products, Regulatory

Almirall To Submit Marketing Authorization Application To EMA For Lebrikizumab In Second Half Of 2022

Published: 06/07/2022 06:11 GMT
Lilly(Eli) & Co (LLY) - Plans to Submit a Marketing Authorization Application (maa) to the European Medicines Agency (ema) for Lebrikizumab in Atopic Dermatitis in the Second Half of 2022.
Lilly Also Plans to Submit an Application to the U.S. Food and Drug Administration (fda) This Year, Followed by Submissions to Other Regulatory Agencies Around the World.
Almirall Has Licensed the Rights to Develop and Commercialize Lebrikizumab for the Treatment of Dermatology Indications, Including Ad, in Europe.
Lilly Has Exclusive Rights for Development and Commercialization of Lebrikizumab in the United States and the Rest of the World Outside Europe.